32 related articles for article (PubMed ID: 38734625)
1. Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.
Shu X; Shao Y; Chen Y; Zeng C; Huang X; Wei R
Front Immunol; 2024; 15():1392956. PubMed ID: 38817600
[TBL] [Abstract][Full Text] [Related]
2. Redox mechanisms in autoimmune thyroid eye disease.
Buonfiglio F; Ponto KA; Pfeiffer N; Kahaly GJ; Gericke A
Autoimmun Rev; 2024 May; 23(5):103534. PubMed ID: 38527685
[TBL] [Abstract][Full Text] [Related]
3. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
Wang R; Song D; Zhong Y; Li H
BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
[TBL] [Abstract][Full Text] [Related]
4. Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study.
Wang Y; Hu H; Chen L; Zhang H; Yang T; Xu X; Chen H
Front Endocrinol (Lausanne); 2022; 13():1079852. PubMed ID: 36743915
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of euthyroid Graves' disease (Review).
Macovei ML; Azis Ű; Gheorghe AG; Burcea M
Exp Ther Med; 2021 Nov; 22(5):1346. PubMed ID: 34630700
[TBL] [Abstract][Full Text] [Related]
6. The IGF-1 Signaling Pathway in Viral Infections.
Józefiak A; Larska M; Pomorska-Mól M; Ruszkowski JJ
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452353
[TBL] [Abstract][Full Text] [Related]
7. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
8. Current Knowledge on Graves' Orbitopathy.
Gontarz-Nowak K; Szychlińska M; Matuszewski W; Stefanowicz-Rutkowska M; Bandurska-Stankiewicz E
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374706
[TBL] [Abstract][Full Text] [Related]
9. The crosstalk between IGF-1R and ER-α in the proliferation and anti-inflammation of nucleus pulposus cells.
Chen RS; Zhang XB; Zhu XT; Wang CS
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):5886-5894. PubMed ID: 32572901
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
11. Immunological Aspects of Graves' Ophthalmopathy.
Łacheta D; Miśkiewicz P; Głuszko A; Nowicka G; Struga M; Kantor I; Poślednik KB; Mirza S; Szczepański MJ
Biomed Res Int; 2019; 2019():7453260. PubMed ID: 31781640
[TBL] [Abstract][Full Text] [Related]
12. The Involvement of NF-κB/Klotho Signaling in Colorectal Cancer Cell Survival and Invasion.
Xie B; Nie S; Hu G; Xiong L; Hu F; Li M; Peng T; Nie J; He Y
Pathol Oncol Res; 2019 Oct; 25(4):1553-1565. PubMed ID: 30612312
[TBL] [Abstract][Full Text] [Related]
13. B cells in Graves' Orbitopathy: more than just a source of antibodies?
Salvi M; Covelli D
Eye (Lond); 2019 Feb; 33(2):230-234. PubMed ID: 30514895
[TBL] [Abstract][Full Text] [Related]
14. Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis.
Wang C; Ning Q; Jin K; Xie J; Ye J
BMC Ophthalmol; 2018 Feb; 18(1):46. PubMed ID: 29452583
[TBL] [Abstract][Full Text] [Related]
15. The interaction of IGF-1/IGF-1R and hydrogen sulfide on the proliferation of mouse primary vascular smooth muscle cells.
Shuang T; Fu M; Yang G; Wu L; Wang R
Biochem Pharmacol; 2018 Mar; 149():143-152. PubMed ID: 29248598
[TBL] [Abstract][Full Text] [Related]
16. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro.
Place RF; Krieger CC; Neumann S; Gershengorn MC
Br J Pharmacol; 2017 Feb; 174(4):328-340. PubMed ID: 27987211
[TBL] [Abstract][Full Text] [Related]
18. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.
Krieger CC; Neumann S; Place RF; Marcus-Samuels B; Gershengorn MC
J Clin Endocrinol Metab; 2015 Mar; 100(3):1071-7. PubMed ID: 25485727
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
